BR Ventures (BRV) is Cornell's student-run venture capital fund, providing a vital connection between intellectual properties and needed financial resources by infusing venture capital and business expertise into promising Cornell and local startups. The Fund provides seed capital, typically ranging between $50,000 and $200,000, to selected businesses. Over its lifetime, BRV will invest up to $10,000,000 in business entities, most of which will be sourced through the extended Cornell community. BRV is funded by donations to the University and returns are used to create a growing pool of investment capital and build the endowment.  The Fund has undertaken several initiatives to facilitate the commercialization of Cornell technology and to expand the scope of entrepreneurship throughout the extended Cornell community. These initiatives include the $25,000 Cornell Venture Challenge, partnering with Cornell's technology transfer office-CCTEC, participation in the Cornell Entrepreneurship and Venture Capital Club's annual symposium, working to build a strong relationship with Entrepreneurship@Cornell, and developing an extensive network among alumni. BRV has also developed informal relationships with a number of unaffiliated later stage venture capital firms and incubators.

Big Red Ventures

Kleiner Perkins is a venture capital firm specializing in investing in early-stage, growth, and incubation companies. The firm continues that legacy, investing in founders with bold ideas that span industries and continents, partnering with them from inception to IPO and beyond to maximize the potential of their ideas. They also focus on early computer firms using their devices and programming and service companies. It also invests in the digital, life sciences, and healthcare industries.

Kleiner Perkins

Sutter Hill Ventures has financed technology-based start-ups and assisted entrepreneurs in building companies since 1962. Through their decades of experience, they have developed strong industry networks, considerable operating and venture capital experience, and an understanding of the challenges that early-stage and high-growth companies face. They offer expertise in developing business strategies and partnerships, building management teams, and financing companies in both public and private markets. They have experienced operating executives who love building companies. Their approach is straightforward. They have a collegial and uncomplicated operating style that is direct and results-driven. They work as a team to respond quickly to new investment proposals and to their portfolio companies needs. Once they invest in a company, they bring to bear their time, expertise, and extensive industry networks to help these companies succeed. Building companies is their top priority and their favorite occupation. They have structured Sutter Hill to allow them to invest in a focused portfolio of early-stage companies and build value for the long term. They are always available to their CEOs and founders as advisors and mentors ready with practical and strategic advice from their own venture capital and operating experiences. They don't insist on winning every argument, but they will always tell you what they think. They also have a network of executives, advisors, and support infrastructure to help their portfolio get going in the right direction quickly. As former line managers themselves, they know the vision, energy, and commitment that building a successful company requires. They strive to build partnerships with entrepreneurs that combine dedicated support from Sutter Hill with trust that the teams they back can make good decisions and execute on the details. Their limited partners have committed long-term support to their evergreen fund which allows them to make long-term commitments to their companies. In addition, a significant portion of every dollar they invest in their own money, and each one of them participates in every investment. This direct investment reinforces each partner's commitment to every company in their portfolio and ensures that they bring every available resource to bear in helping their companies succeed.

Sutter Hill Ventures

Alloy Ventures is an early stage venture capital firm that invests in the areas of life sciences, information technology, and cleantech.

Alloy Ventures

[AllianceBernstein](http://www.alliancebernstein.com) is a publicly traded global asset management firm, with approximately $735 billion in assets under management at March 31, 2008.

AllianceBernstein

Maverick Ventures is the venture arm of multi-billion dollar investment firm Maverick Capital. Combining the resources of a global firm with the benefits of an agile, focused team, Maverick Ventures supports entrepreneurs from seed through maturity. With over 30 years of early-stage investment experience, the Maverick Ventures team has funded more than 100 companies in the healthcare, software and deep technology sectors. The highly-experienced team of operating executives and investors at Maverick Ventures generally lead rounds, take board seats and work with management to build successful enterprises.

Maverick Ventures

The DAG (Duff Ackerman & Goodrich) Ventures partnership began with investments in the cable TV, infrastructure, media, and wireless industries in the 1980's. The firm now invests in a variety of technology companies.

DAG Ventures

Morgan Stanley, from the number of their offices and employees to the experience of their management and the quality of their financial results, the facts about Morgan Stanley tell an impressive story.  Morgan Stanley and its people have helped redefine the meaning of financial services. The firm has continually broken new ground in advising its clients on strategic transactions, pioneering the global expansion of finance and capital markets, and providing new opportunities for individual and institutional investors.  Morgan Stanley maintained comprehensive corporate governance guidelines for years before corporate governance became headline news.

Morgan Stanley

T. Rowe Price is an investment management firm dedicated to funding technology startups. The firm serves individuals, financial intermediaries, and institutions and offers a full range of investment strategies across a broad spectrum: debt, equities, and private equities.

T. Rowe Price

Intel Capital invests in innovative startups targeting cloud and AI infrastructure, edge, 5G, autonomy, cybersecurity, client & gaming, enterprise applications, silicon design and manufacturing, and a wide range of other disruptive technologies.

Intel Capital

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Wellcome Trust

Monsanto specializes in providing agricultural products. Their agricultural products are intended to help farmers grow crops while using energy, water, and land. They also provide seeds, traits, software, and crop protection products, thereby helping farmers improve yield.

Monsanto

Ontario Teachers' Pension Plan invests and administers the pensions of active and retired teachers. It invests the pension fund's assets and administers the pensions of 284,000 active and retired teachers in Ontario. A pension plan has existed for Ontario teachers since 1917. Today, the plan's members include 173,000 teachers in elementary and secondary schools in Ontario, 111,000 pensioners, and 72,000 inactive members. The plan has one of Canada's largest payrolls with $4.2 billion in benefits paid to plan members and $2.3 billion received in total contributions from teachers and the provincial government in 2008.

Ontario Teachers' Pension Plan

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

Deerfield

For 30 years the _Mohr Davidow Ventures team has invested in early stage technology-based startups that redefine or create large new markets. They believe that emerging information technology innovations are enabling a decade-long opportunity to invest in the “Era of Digital Engagement,” one in which personal, commercial, and public sector interactions of all kinds will be profoundly reengineered to leverage the power of mobile devices, cloud computing, and data analytics.  The Firm seeks to identify and partner with exceptional entrepreneurs who leverage these technologies to build companies where seamless, deep engagement with customers will create billion dollar markets in a number of different verticals. These verticals include: Digital Marketing, Advertising, & Media, Collaborative Enterprise Applications, The Digitization of Education and Health, Digital Financial Services, E‐commerce & Digital Retail Innovation, Mobile/Web‐Powered “LifeTech.” The Firm also has previous investments in the innovative life sciences & genomics space.  Leading companies funded by Mohr Davidow Ventures includes: Agile (Acquired by NYSE: ORCL); Aryaka Networks; Brocade; Coupa; Genomatica; HealthTap; Infusionsoft; Kabbage; nLight; ONI Systems (Acquired by NASDAQ: CIEN); Proofpoint (NASDAQ: PFPT); Rally Software (NYSE: RALY); Rocket Fuel (NASDAQ: FUEL); Rambus; Shutterfly (NASDAQ: SFLY); Ticketfly; Verinata Health (Acquired by NASDAQ: ILMN); and Visible Measures. The Firm has $1.85 billion under management.

Mohr Davidow Ventures

Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company markets and sells its clinical diagnostic products in the United States directly and outside the United States primarily through distributors, as well as through its direct sales force, and the company also markets and sells its other products through collaborative partners. The company's blood screening products are marketed and distributed worldwide by Novartis. In addition, the company has agreements with Siemens (as assignee of Bayer Corporation), bioMÃ©rieux, Inc., or bioMÃ©rieux, and Fujirebio, Inc., through its subsidiary Rebio Gen, Inc., or Rebio Gen, to market products in various overseas markets. The company is developing NAT assays and instruments for the detection of harmful pathogens in the environment and biopharmaceutical and beverage manufacturing processes. The company has entered into collaboration agreements with GE Infrastructure Water and Process Technologies, or GEI, a unit of General Electric Company, and Millipore Corporation, or Millipore, under which the company would be primarily responsible for developing and manufacturing assays for exclusive use or sale by its collaborative partners in specified fields with in the industrial testing market. Products The company has applied its core technologies to develop multiple product lines, all of which utilize its expertise in NAT probes, sample collection and processing. The company categorizes its products into clinical diagnostic products and blood screening products. Clinical Diagnostic Products Within its clinical diagnostic product group, the company has developed products for the detection of non-viral and viral microorganisms and for the detection of markers for cancer. Clinical Diagnostic Products for the Detection of Non-Viral Microorganisms The company has developed FDA-approved amplified and non-amplified NAT assays that detect non-viral micro-organisms primarily for use in clinical diagnostics. The company's principal products for the detection of non-viral microorganisms include its non-amplified AccuProbe and PACE family of products and its amplified Mycobacterium Tuberculosis Direct Test and amplified APTIMA products. AccuProbe Products: The company's AccuProbe Culture Identification products are tools for the identification of mycobacterial, fungal and bacterial pathogens, with sensitivities and specificities approaching 100% in most cases. These products allow for the detection of target organisms from primary cultures, eliminating the additional labor of purifying secondary cultures. All AccuProbe Culture Identification assays are based on its HPA technology. As part of its AccuProbe Culture Identification product line, the company also has developed a procedure to detect GBS from broth culture. Group A Streptococcus Direct: The Group A Streptococcus Direct Test, or GASDirect assay, is a NAT assay for the direct detection of Streptococcus pyogenes in one hour from a throat swab. PACE Product Family: The company's PACE 2C offers the testing for both chlamydia infections and gonorrhea from a single patient specimen.

Gen-Probe

Deerfield Capital Management (''DCM'') is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1993.

Deerfield Capital Management

Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.

Redmile Group

PacBio

PacBio designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.

<div>Pacific Biosciences of California (PacBio) is a biotechnology company specializing in developing and manufacturing advanced sequencing systems. PacBio is known for its Single Molecule, Real-Time (SMRT) sequencing technology, which enables accurate long-read sequencing. The company&rsquo;s offerings include the HiFi long-read sequencing technology and the emerging short-read Sequencing by Binding (SBB) technology, used in various applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. In 2021, PacBio expanded its technology portfolio through the acquisition of Omniome, a biotechnology company developing a proprietary short-read sequencing platform.</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

PacBio launches Vega benchtop long-read sequencing platform.. PacBio.. product 

ARTBIO

Announced a partnership to develop cancer therapies. The financial terms of the agreement have not been disclosed; however, both parties have agreed to contribute equally across all stages from research to commercialization.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Corteva Agriscience

Corteva Agriscience and PacBio have collaborated to develop high-throughput workflows for plant and microbial genome sequencing.

Enhancing seed and crop traits via biotechnology

Crop Biotech

Companies that develop a platform to insert, edit, or delete the DNA of a plant itself using approaches such as CRISPR-Cas 9, TALENs, and Zinc Fingers. These approaches help develop plant genes or seeds with traits such as disease-resistant, enhanced-performance, or improve yield.

PacBio collaborates with Corteva Agriscience to develop high-throughput DNA sequencing workflows for plant, pest, and microbial genomics, aiming to enhance efficiency in characterizing complex genomes and supporting Corteva's agricultural research and production.

<div>
 
 Pacific Biosciences of California (PacBio) is a biotechnology company specializing in developing and manufacturing advanced sequencing systems. PacBio is known for its Single Molecule, Real-Time (SMRT) sequencing technology, which enables accurate long-read sequencing. The company&rsquo;s offerings include the HiFi long-read sequencing technology and the emerging short-read Sequencing by Binding (SBB) technology, used in various applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. In 2021, PacBio expanded its technology portfolio through the acquisition of Omniome, a biotechnology company developing a proprietary short-read sequencing platform.
 
 
 Since October 2010, the company has been operating as a public listed company. It is traded on the Nasdaq under the ticker symbol PACB.
 
 
 Key customers and partnerships
 
 
 PacBio's sequencing solutions cater to research scientists in the academia, biotechnology, and pharmaceutical industries as well as healthcare providers. The company has engaged in several partnerships to advance genomic science, including a partnership with Estonia National Biobank entered in March 2024, which entailed the use of PacBio's Revio HiFi sequencing system for sequencing 10,000 whole genomes to develop personalized medicine in areas such as cardiology and mental health​.
 
 
 Funding and financials
 
 
 The company last raised funding in August 2023 when it raised USD 85 million in a post-IPO equity round. The investors or the intended use of funds were not disclosed.
 
 
 In FY2023, the company reported a revenue of USD 200.5 million with a 56% YoY growth. The company spent USD 187.1 million on R&amp;D. The operating loss for the year was USD 334.4 million.
 
 
 
</div>

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>

PacBio has introduced Vega, its debut benchtop long-read sequencing platform, which is priced at USD 169,000. The product is designed to make highly accurate sequencing accessible to researchers.
Using HiFi technology, Vega promises swift turnaround times. The platform mirrors the capabilities of PacBio’s high-throughput sequencer, Revio, but in a smaller, lower-throughput benchtop format. It can be utilized for a variety of applications including small genome sequencing, targeted sequencing, and RNA sequencing. The platform is also compatible with the pre-existing HiFi ecosystem used for library preparation and data analysis.

</div>

PacBio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless